Decoding Congestion in Heart Failure: Novel Insights for Clinicians in 30 Minutes

This session will provide an overview of recent advancements in assessing and managing congestion in patients with heart failure. Congestion remains a primary driver of hospital admissions in this population and a key determinant of clinical outcomes. In recent years, substantial efforts have been made to optimize diuretic therapy, including the evaluation of combination strategies (e.g., ADVOR, CHLOROTIC, DICATE-AHF trials) and alternative routes of administration, such as subcutaneous and intranasal formulations.

Parallel advances have focused on predicting diuretic resistance and enhancing precision congestion monitoring. These include pulmonary artery pressure monitoring devices (e.g., CardioMEMS, Cordella), inferior vena cava size assessment technologies (e.g., the Fire1 system), and point-of-care ultrasound. Additionally, emerging and investigational strategies such as the RenalGuard system and negative-pressure diuresis are being explored for their potential clinical utility. Although covered in other areas of the program, subcutaneous furosemide and intranasal bumetanide should also be mentioned.

Agenda

• Moderator - TBD
• Moderator - Teri Diederich, NP, FHFSA, HF-Cert
• Assessing Congestion in Heart Failure: An Update on Emerging Device Technologies - Gabriel Sayer, MD
• Decongestive Therapies for Heart Failure in 2025: Where We Are and Where We’re Headed - Dan Bensimhon, MD
• Panel Discussion